The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience

References

• Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–S8.
   PubMed Web of Science ®Google Scholar
• Slamon J, Clark M, Wong G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Atalay G, Cardoso F, Awada A, et al. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003; 14(9):1346–1363.
   PubMed Web of Science ®Google Scholar
• Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673–1684.
   PubMed Web of Science ®Google Scholar
• Geyer E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733–2743.
   PubMed Web of Science ®Google Scholar
• Blackwell K, Burstein H, Storniolo A, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30(21):2585–2592.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)). Ann Oncol. 2020;31(12):1623–1649.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim K, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366(2):109–119.
   PubMed Web of Science ®Google Scholar
• Swain M, Kim B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471.
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791.
   PubMed Web of Science ®Google Scholar
• Zielińska M, Zarankiewicz N, Kosz K, et al. HER2-positive breast cancer – available anti-HER2 therapies and new agents under investigation. J Pre Clin Clin Res. 2020;14(2):44–48. DOI:.
   Google Scholar
• Tiwari R, Mishra P, Abraham J. Neratinib, a novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer. 2016;16(5):344–348.
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, Feng YH, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial. J Clin Oncol. 2019;37(15_suppl):1002–1002.
   Web of Science ®Google Scholar
• Murthy K, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.
   PubMed Web of Science ®Google Scholar
• Lin U, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–2619.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Im SA, Cardoso F, et al. Phase 3 SOPHIA study of margetuximab + chemotherapy vs. trastuzumab + chemotherapy in patients with HER2+ metastatic breast second interim overall survival analysis. Cancer Res. 2020;80(4 suppl):abstr GS1-02.
   Web of Science ®Google Scholar
• Vallecillo L, Raghavendra A, Hess K, et al. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019;176(1):227–234.
   PubMed Web of Science ®Google Scholar
• Xinyu G, Huiping L, Ying Y, et al. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncol Lett. 2020; 20(6):378.
   PubMed Web of Science ®Google Scholar
• Pernas S, Tolaney M. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:1–16.
   Web of Science ®Google Scholar
• Yardley DA, Kaufman PA, Brufsky A, et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive breast cancer. Breast Cancer Res Treat. 2014;145(3):725–734.
   PubMed Web of Science ®Google Scholar
• Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217–233.
   PubMed Web of Science ®Google Scholar
• Giuliano M, Trivedi V, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care (Basel)). 2013;8(4):256–262.
   PubMed Web of Science ®Google Scholar
• Schnitt S. Traditional and newer pathologic factors. J Natl Cancer Inst. 2001;2001(30):22–26.
   Google Scholar
• Perez A, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-Positive, advanced breast cancer: Primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141–148.
   PubMed Web of Science ®Google Scholar
• Greil R, Borštnar S, Petráková K, et al. Combination therapy of lapatinib and capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: Results from the lapatinib expanded access program (LEAP) in Central and Eastern Europe. Onkologie. 2011;34(5):233–238.
   PubMedGoogle Scholar